Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Critical Week Ahead for NCR Voyix and NCR Atleos Shareholders

Robert Sasse by Robert Sasse
October 29, 2025
in Analysis, Earnings, Tech & Software
0
NCR Stock
0
SHARES
14
VIEWS
Share on FacebookShare on Twitter

Investors in both NCR Voyix and NCR Atleos are bracing for a pivotal period as the companies prepare to release their quarterly financial results. Market expectations are running high for both entities, setting the stage for significant price movements based on their upcoming earnings disclosures.

Earnings Schedule and Corporate Developments

NCR Voyix will unveil its quarterly performance on November 6, with the announcement scheduled before market opening. Following the release, management will host a conference call to provide investors with detailed insights into the digital commerce specialist’s current operational standing.

Meanwhile, NCR Atleos is set to report its third-quarter 2025 results after market close on November 5. A management call for analysts and investors will occur the following morning. In a separate development, Atleos recently implemented comprehensive amendments to its corporate governance framework, primarily affecting procedures for shareholder proposals and director nominations.

Recent Trading Activity and Corporate Structure

During the previous trading session, both equities experienced modest downward pressure. NCR Voyix shares declined by 0.92% to close at $11.80, fluctuating between $11.73 and $11.95 throughout the day. Similarly, NCR Atleos finished 0.75% lower at $37.85.

Should investors sell immediately? Or is it worth buying NCR?

The upcoming earnings represent another critical test for both companies since becoming independent entities following their separation in October 2023. The strategic rationale behind the split positioned Voyix to concentrate exclusively on digital commerce solutions, while Atleos focuses on self-service banking through automated teller machines.

Analyst Sentiment and Market Outlook

Market professionals maintain a positive stance toward NCR Voyix, with six research analysts currently recommending the stock as a “Buy.” Their collective assessment points to substantial upside potential, reflected in an average price target of $15.17. Although recent trading has shown increased volatility, the overall technical picture remains favorable.

The central question facing investors is whether the imminent quarterly reports will validate this optimistic market positioning. The forthcoming week promises to establish the directional trend for both successors of the former NCR corporation, with their financial results likely determining near-term share price trajectories.

Ad

NCR Stock: Buy or Sell?! New NCR Analysis from February 7 delivers the answer:

The latest NCR figures speak for themselves: Urgent action needed for NCR investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

NCR: Buy or sell? Read more here...

Tags: NCR
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Arcutis Biotherapeutics Stock

Arcutis Biotherapeutics: From Losses to Profitability in Stunning Turnaround

Nuvation Bio Stock

Clinical Trial Progress Fuels Nuvation Bio's Remarkable Rally

Workiva Stock

Workiva Shares Face Critical Test Amid Investor Pressure

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com